In asthma, increased inflammation, as measured by the SII, is independently linked to greater mortality risk (all-cause, CV and respiratory).

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

Exhaled Nitric Oxide and Sputum Eosinophils are Complementary Tools for Diagnosing Occupational Asthma suggests a study published in the Allergy.Exposure-related changes in exhaled nitric ...

A study reveals that shape-shifting immune cells, intermediate ILC2s, may contribute to severe asthma and resistance to ...

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- A set of chameleon-like immune cells could be contributing to severe asthma in ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...